Caruso G.I.a· Korde D.S.b· Humpel C.b

Author affiliations

aDepartment of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy
bDepartment of Psychiatry I, Medical University Innsbruck, Innsbruck, Austria

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Received: July 18, 2022
Accepted: October 28, 2022
Published online: February 01, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Abstract

The nucleus basalis of Meynert (nBM) is the major source of cholinergic neurons in the basal forebrain, which require nerve growth factor (NGF) for their survival. Melatonin, a pleiotropic hormone, has been shown to exert neuroprotection in several experimental models, but its effect on nBM neurons is not well known. Thus, the aim of this study is to evaluate the effect of melatonin in organotypic brain slices of the nBM. Organotypic nBM slices were incubated for 2 weeks without (control) or with 100 ng/mL NGF, 1 μM melatonin, or a combination of both. Cholinergic neurons were immunohistochemically stained for choline acetyltransferase (ChAT) and subjected to a co-localization study with silent information regulator 1 (SIRT1) and melatonin receptor 1A (MT1A), both potentially involved in melatonin neuroprotection. Counting of ChAT-positive neurons in nBM slices showed that melatonin and NGF significantly increased the number of ChAT-positive neurons compared to the control in a dose-dependent manner (1–10 μM). In co-treatment with NGF, melatonin did not potentiate the maximal NGF-mediated effect. Immunohistochemical analysis proved that cholinergic nBM neurons co-localized with SIRT1 and MT1A receptor. Our data show that melatonin improves the survival of cholinergic nBM neurons and confirm that they express SIRT1 and MT1A.

© 2023 S. Karger AG, Basel

References Armstrong DM, Saper CB, Levey AI, Wainer BH, Terry RD. Distribution of cholinergic neurons in rat brain: demonstrated by the immunocytochemical localization of choline acetyltransferase. J Comp Neurol. 1983;216(1):53–68. Kimura H, McGeer PL, Peng F, McGeer EG. Choline acetyltransferase-containing neurons in rodent brain demonstrated by immunohistochemistry. Science. 1980;208(4447):1057–9. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol. 1983;214(2):170–97. Rye DB, Wainer BH, Mesulam MM, Mufson EJ, Saper CB. Cortical projections arising from the basal forebrain: a study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase. Neuroscience. 1984;13(3):627–43. Koulousakis P, Andrade P, Visser-Vandewalle V, Sesia T. The nucleus basalis of Meynert and its role in deep brain stimulation for cognitive disorders: a historical perspective. J Alzheimers Dis. 2019;69(4):905–19. Isaev NK, Stelmashook EV, Genrikhs EE. Role of nerve growth factor in plasticity of forebrain cholinergic neurons. Biochemistry. 2017;82(3):291–300. Foidl BM, Ucar B, Schwarz A, Rebelo AL, Pandit A, Humpel C. Nerve growth factor released from collagen scaffolds protects axotomized cholinergic neurons of the basal nucleus of Meynert in organotypic brain slices. J Neurosci Methods. 2018;295:77–86. Humpel C, Weis C. Nerve growth factor and cholinergic CNS neurons studied in organotypic brain slices. Implication in Alzheimer’s disease? J Neural Transm Suppl. 2002;62:253–63. Chen D, Zhang T, Lee TH. Cellular mechanisms of melatonin: insight from neurodegenerative diseases. Biomolecules. 2020;10(8):1158. Alghamdi BS. The neuroprotective role of melatonin in neurological disorders. J Neurosci Res. 2018;96(7):1136–49. Feng Z, Chang Y, Cheng Y, Zhang BL, Qu Z, Qin C, et al. Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer’s disease. J Pineal Res. 2004;37(2):129–36. Feng Z, Cheng Y, Zhang JT. Long-term effects of melatonin or 17 beta-estradiol on improving spatial memory performance in cognitively impaired, ovariectomized adult rats. J Pineal Res. 2004;37(3):198–206. Shen D, Tian X, Sang W, Song R. Effect of melatonin and resveratrol against memory impairment and hippocampal damage in a rat model of vascular dementia. Neuroimmunomodulation. 2016;23(5–6):318–31. Matsubara E, Bryant-Thomas T, Quinto JP, Henry TL, Poeggeler B, Herbert D, et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem. 2003. 85(5):1101–8. Dominguez-Alonso A, Ramirez-Rodriguez G, Benitez-King G. Melatonin increases dendritogenesis in the hilus of hippocampal organotypic cultures. J Pineal Res. 2012;52(4):427–36. Hoppe JB, Frozza RL, Horn AP, Comiran RA, Bernardi A, Campos MM, et al. Amyloid-beta neurotoxicity in organotypic culture is attenuated by melatonin: involvement of GSK-3beta, tau and neuroinflammation. J Pineal Res. 2010;48(3):230–8. Buendia I, Parada E, Navarro E, Leon R, Negredo P, Egea J, et al. Subthreshold concentrations of melatonin and galantamine improves pathological AD-hallmarks in hippocampal organotypic cultures. Mol Neurobiol. 2016;53(5):3338–48. Ullrich C, Daschil N, Humpel C. Organotypic vibrosections: novel whole sagittal brain cultures. J Neurosci Methods. 2011;201(1):131–41. Chao MV, Hempstead BL. p75 and Trk: a two-receptor system. Trends Neurosci. 1995;18(7):321–6. Chu Y, Cochran EJ, Bennett DA, Mufson EJ, Kordower JH. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer’s disease. J Comp Neurol. 2001;437(3):296–307. Jette N, Cole MS, Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer’s disease patients. Brain Res Mol Brain Res. 1994;25(3–4):242–50. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer’s disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neurosci. 1995;15(9):6213–21. Erşahin M, Ozdemir Z, Ozsavcı D, Akakın D, Yeğen BC, Reiter RJ, et al. Melatonin treatment protects against spinal cord injury induced functional and biochemical changes in rat urinary bladder. J Pineal Res. 2012;52(3):340–8. Olivieri G, Otten U, Meier F, Baysang G, Dimitriades-Schmutz B, Muller-Spahn F, et al. Oxidative stress modulates tyrosine kinase receptor A and p75 receptor (low-affinity nerve growth factor receptor) expression in SHSY5Y neuroblastoma cells. Neurol Clin Neurophysiol. 2002;2002(2):2–10. Wu YH, Zhou JN, Balesar R, Unmehopa U, Bao A, Jockers R, et al. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone. J Comp Neurol. 2006;499(6):897–910. Lacoste B, Angeloni D, Dominguez-Lopez S, Calderoni S, Mauro A, Fraschini F, et al. Anatomical and cellular localization of melatonin MT1 and MT2 receptors in the adult rat brain. J Pineal Res. 2015;58(4):397–417. Carpenter G, Liao HJ. Receptor tyrosine kinases in the nucleus. Cold Spring Harb Perspect Biol. 2013;5(10):a008979. Magalhaes AC, Dunn H, Ferguson SS. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br J Pharmacol. 2012;165(6):1717–36. Caruso GI, Spampinato SF, Costantino G, Merlo S, Sortino MA. SIRT1-Dependent upregulation of BDNF in human microglia challenged with aβ: an early but transient response rescued by melatonin. Biomedicines. 2021;9(5):466. Merlo S, Luaces JP, Spampinato SF, Toro-Urrego N, Caruso GI, D’Amico F, et al. SIRT1 mediates melatonin's effects on microglial activation in hypoxia: in vitro and in vivo evidence. Biomolecules. 2020;10(3):364. Michan S, Li Y, Chou MM, Parrella E, Ge H, Long JM, et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J Neurosci. 2010;30(29):9695–707. Herskovits AZ, Guarente L. SIRT1 in neurodevelopment and brain senescence. Neuron. 2014;81(3):471–83. Gomes BAQ, Silva JPB, Romeiro CFR, Dos Santos SM, Rodrigues CA, Goncalves PR, et al. Neuroprotective mechanisms of resveratrol in Alzheimer’s disease: Role of SIRT1. Oxid Med Cell Longev. 2018;2018:8152373. Zhang SJ, Xu TT, Li L, Xu YM, Qu ZL, Wang XC, et al. Correction: bushen-Yizhi al. formula ameliorates cognitive dysfunction through SIRT1/ER stress pathway in SAMP8 mice. Oncotarget. 2020;11(27):2684–5. Wang J, Zhang Y. Neuroprotective effect of berberine agonist against impairment of learning and memory skills in severe traumatic brain injury via Sirt1/p38 MAPK expression. Mol Med Rep. 2018;17(5):6881–6. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y. Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem. 2007;282(9):6823–32. Sugino T, Maruyama M, Tanno M, Kuno A, Houkin K, Horio Y. Protein deacetylase SIRT1 in the cytoplasm promotes nerve growth factor-induced neurite outgrowth in PC12 cells. FEBS Lett. 2010;584(13):2821–6. Article / Publication Details

First-Page Preview

Received: July 18, 2022
Accepted: October 28, 2022
Published online: February 01, 2023

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: https://www.karger.com/PHA

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.